UDoTest is proud to announce that they were recognised as one of the top 5 (out of 70 applicants) global organisations contributing to the fight against cervical cancer in April 2016.
The Quest awards were started by leading global biotechnology firm, Genentech, who discover, develop, manufacture and commercialise medicines which treat patients with serious or life-threatening medical conditions. Their goal was to solicit bold new solutions from start-up and healthcare communities in an effort to identify viable and impactful solutions in the fight against cervical cancer.
The Quest Awards aimed to uncover effective ways to reduce the number of women dying from cervical cancer in the United States. Their goal was to:
Grant the Quest Award to an organization who identifies a viable and impactful option in the fight against cervical cancer.
Pilot patient education techniques to increase awareness and screening rates.
Out of 70 world-wide applicants, UDoTest came in the top 5 at the global cervical cancer Quest Awards this April in San Francisco. Being the only nominee based outside of the US and Canada, and sharing a stage with organisations like Duke University, Eve Medical, Mobile ODT and Antiva, UDoTest was able to share meaningful context on cervical cancer awareness in the sub-Saharan African region.
As an organisation that is driven by finding innovative ways to save lives, the UDoTest team returned from San Francisco with a renewed passion and immense pride for being associated with such a prestigious award. The goal of substantially increasing the cervical cancer survival rate through earlier diagnosis is undoubtedly within reach.
For more details read here: http://www.thequestaward.com